Weight loss therapeutics Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Weight loss therapeutics Market is segmented By Approved Drug Formulations (Liraglutide, Buproprion and naltrexone, Lorcaserin, Phentermine and topiramate), By Distribution Channels (Hospitals , Specialized Clinics, Retail Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Weight loss therapeutics Market Overview

The Global Weight Loss Therapeutics Market reached USD 2,798.0 million in 2022 and is projected to witness lucrative growth by reaching up to USD 14,978.1 million by 2031. The global weight loss therapeutics market is expected to exhibit a CAGR of 24.3% during the forecast period (2024-2031). The weight loss therapeutics market trends show rising demand for these owing to the rising prevalence of chronic diseases and increasing research and development.

Furthermore, the numerous lifestyle changes, together with rising demand for treatment at the point of care, are driving up the weight loss therapeutics market size. 

Due to the expansion of research in these fields, the market is seeing an increase in demand from North American regions. With significant competitors like F Hoffmann-la Roche Ltd, Altimmune, Viking Therapeutics, and others actively operating in the market, the competitive struggle is escalating the weight loss therapeutics market growth.   

Weight Loss Therapeutics Market Scope

To Know More Insights - Download Sample

Weight loss therapeutics Market Dynamics

The Rising Clinical Trials by Key Companies Drive the Growth of the Weight Loss Therapeutics Market

The rising incidence of chronic disorders, together with increasing demand for treatment at the point of care, recent developments in therapeutics, sruging clinical trials and novel product launch, are likely to fuel global weight loss therapeutics market size expansion throughout the course of the forecast period.

The Vikings Therapeutics is creating a novel class of dual agonists for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors in an effort to treat numerous metabolic illnesses, including obesity, NASH, and a few uncommon diseases. The medication candidate in its primary clinical study is VK2735. 

Data from a Phase 1 trial assessing VK2735 (subcutaneously dosed) for metabolic diseases were released in the first quarter of 2023, and they showed a promising safety and tolerability profile as well as encouraging signals of therapeutic efficacy. The business intends to start a Phase 2 investigation of VK2735 among individuals with obesity in the middle of 2023 based on these encouraging preliminary data.

The Change in Food Habits and Lifestyle Creates Lucrative Opportunities  for Manufacturers

There is a growing weight loss therapeutics market opportunity owing to rising advancements and changes in lifestyle owing to the changing world. The rising prevalence of various disorders such as diabetes and obesity among adults is also a weight loss therapeutics market trend driving the market. 

An increased protein, lower carbohydrate diet may have some advantages in studies where participants have free reign over their diet. However, the quality and sources of these nutrients matter more for the prevention of chronic diseases than their relative amounts in the diet. Additionally, according to the most recent hospitals, weight control is addressed in a similar diet quality message. 

In the past 30 years, Americans' diets have consumed fewer calories from fat, but rates of obesity have increased dramatically. The primary focus of treatment continues to be lifestyle modifications, which are crucial for maintaining weight loss over the long term.

Limited Efficiency of the Drugs and the Side Effects will Hamper the Growth of the Market

Although immensely useful, weight loss drugs do have some drawbacks. Diethylpropion and phentermine are stimulant-type weight-loss drugs that are only advised for short-term usage (up to 12 weeks) due to the possibility of additional adverse effects and dependence. Orlistat (Alli, Xenical) is often used for longer-term weight loss, which may also include maintaining a previously achieved weight loss goal. Alli is also available over-the-counter at pharmacies. 

Phentermine and topiramate (Qsymia), bupropion and naltrexone (Contrave), and liraglutide (Saxenda) are prescription weight-reduction medications used for persistent, long-term weight loss, but only if adequate results are shown. After 12 to 16 weeks, if a 3% to 4% weight loss goal has not been met, long-term treatment is routinely discontinued. These factors limit market expansion during the anticipated term.

Weight loss therapeutics Market Segment Analysis

The global weight loss therapeutics market is segmented based on approved drugs, distribution channels and region.

Owing to Availability, The Hospital Pharmacies Segment Accounted For Approximately 38.7% Of The Weight Loss Therapeutics Market Share In 2022.

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online pharmacies. Due to the rise in demand for infectious diseases and cardiovascular diseases, weight loss therapeutics is the most rapidly expanding industry. Due to the increasing rising number of chronic disorders associated with obesity, the hospital pharmacies segment held the greatest market share in the global weight loss therapeutics market. 

Diabetes and heart disease are both greatly accelerated by obesity. Key treatment objectives in the treatment of obesity and its comorbidities, particularly type 2 diabetes, are weight loss and maintenance. Unfortunately, some hormonal changes brought on by weight reduction can promote weight return and prevent continued weight loss. The elements of contraindications, side effects, and drug interactions must be kept in mind while choosing the appropriate anti-obesity medication for a particular patient. 

Additionally, medical professionals should think about weight-neutral or weight-reducing drugs that can support patients' efforts to lead better lifestyles and examine the weight impact of pharmacotherapy in the treatment of obesity-related comorbidities. It requires appropriate direction and care, both of which can be found in hospital pharmacies. The top chemists are available in hospital pharmacies, who can advise patients on the best weight reduction therapies based on their needs.

Weight Loss Therapeutics Market Geographical Penetration

North America Accounted for Approximately 42.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for weight loss therapeutics for treatment purposes in healthcare, manufacturers in North America have a chance of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for weight loss therapeutics. 

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for treatment, and increase in biopharmaceutical establishment across the region are also contributing to the growth of weight loss therapeutics market share of this region. 

The primary healthcare organizations and businesses' joint research endeavors as well as new product development that continuously aims to enhance available treatment options are also expected to contribute to the rising demand. Individuals are becoming more aware of various advanced techniques that are being studied for the treatment leading to the expansion of the market in this region.

Weight loss therapeutics Companies

The major global players in the weight loss therapeutics market include F Hoffmann-la Roche Ltd, Currax Pharmaceuticals LLC, Viking Therapeutics, Pfizer Inc., Eli Lilly and Company, Altimmune, VIVUS LLC, Rhythm Pharmaceuticals, Amgen Inc. and Zealand Pharma A/S among others. 

COVID-19 Impact on Weight loss therapeutics Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global weight loss therapeutics market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global weight loss therapeutics market growth over the forecast period.

Key Developments

• In May 2023, headline findings from a phase 3a trial, OASIS 1 in the worldwide OASIS program, were released by Novo Nordisk, a Denmark-based healthcare company. In the 68-week effectiveness and safety trial known as OASIS 1, 667 persons with obesity or overweight and one or more comorbid conditions were randomized to receive either once daily orally administered semaglutide 50 mg for weight control or a placebo. Both therapy modalities included a lifestyle modification component. By showing substantial and greater weight loss using oral semaglutide 50 mg over placebo at week 68, the trial met its primary aim.
• On April 27, 2023, Eli Lilly and Company, a biopharmaceutical company, announced that according to results from SURMOUNT-2, tirzepatide (10 mg and 15 mg) produced greater weight loss when compared with placebo at eighteen months of treatment. For tirzepatide in comparison with placebo for both estimands, the study achieved both co-primary aims and all significant secondary objectives. For the efficacy estimandii, those receiving tirzepatide lost as much as 15.7% (34.4 lb or 15.6 kg) of their body weight. The second international phase 3 clinical trial evaluating the safety and efficacy of tirzepatide for the management of chronic weight is called SURMOUNT-2.  
• On December 1, 2022, AMG 133 is a brand-new glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent bispecific insulinotropic polypeptide receptor antagonist (GIPR) chemical that Amgen, a biotechnology company, just revealed new Phase 1 results from. This first-in-human research (NCT04478708) aimed to assess the pharmacokinetic, pharmacodynamic, and safety profiles of AMG 133 in obese individuals without diabetes. At the minimal dose (140 mg Q4W), the mean percent shifts in body weight (BW) were -7.2%; at the maximum dose (420 mg Q4W), they were -14.5% by day 85. A significant amount of weight loss persisted after the therapy term.

Why Purchase the Report?

• To visualize the global weight loss therapeutics market segmentation based on approved drugs, distribution channels and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of weight loss therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global weight loss therapeutics market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies